Low Molecular Weight Heparin (LMWH)
Low Molecular Weight Heparin (LMWH) is a pharmaceutical drug with 8 clinical trials. Currently 1 active trials ongoing. Historical success rate of 83.3%.
Success Metrics
Based on 5 completed trials
Phase Distribution
Phase Distribution
0
Early Stage
3
Mid Stage
1
Late Stage
Highest Phase Reached
Phase 3Trial Status & Enrollment
83.3%
5 of 6 finished
16.7%
1 ended early
1
trials recruiting
8
all time
Detailed Status
Development Timeline
Analytics
Development Status
Trials by Phase
Trials by Status
Recent Activity
A Study of Amivantamab in Participants With Advanced or Metastatic Solid Tumors Including Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer
Delivery and Implementation of a Randomised Crossover Trial on Thrombosis
Observational Studies in Cancer Associated Thrombosis for Rivaroxaban - United States Cohort
PREVENTion of Clot in Orthopaedic Trauma
A Study to Gather Information About Rivaroxaban in Patients in Sweden With Cancer Who Also Have Thrombosis (OSCAR-SE)
Clinical Trials (8)
A Study of Amivantamab in Participants With Advanced or Metastatic Solid Tumors Including Epidermal Growth Factor Receptor (EGFR)-Mutated Non-Small Cell Lung Cancer
Delivery and Implementation of a Randomised Crossover Trial on Thrombosis
Observational Studies in Cancer Associated Thrombosis for Rivaroxaban - United States Cohort
PREVENTion of Clot in Orthopaedic Trauma
A Study to Gather Information About Rivaroxaban in Patients in Sweden With Cancer Who Also Have Thrombosis (OSCAR-SE)
A Study of the Safety and Pharmacokinetics of Apixaban Versus Vitamin K Antagonist (VKA) or Low Molecular Weight Heparin (LMWH) in Pediatric Subjects With Congenital or Acquired Heart Disease Requiring Anticoagulation
Anticoagulation Length in Cancer Associated Thrombosis
Hemorrhage Risk Prescribed Arixtra
All 8 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 8